未登录.png)
分享.png)
收藏Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional 3+7 intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial比较ABC-14方案（azacitidine、venetoclax和chidamide）与传统3+7强化诱导方案或AB-14方案（venetoclax联合azacitidine）在初诊AML中的疗效和安全性：一项前瞻性、多中心、随机、开放标签临床研究的方案
Yan, Honghong; Huang, Xin; Wu, Ping; Deng, Chengxin; Li, Minming; Lai, Peilong; Du, Xin; Weng, Jianyu 分享 收藏 分享 收藏 Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies优化car-t细胞治疗实体瘤: 当前挑战和潜在策略Ai, Kexin; Liu, Bowen; Chen, Xiaomei; Huang, Chuxin; Yang, Liping; Zhang, Weiya; Weng, Jianyu; Du, Xin; Wu, Kongming; Lai, Peilong 分享 收藏 Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen单细胞分析揭示了经ABC-14方案治疗的复发/难治性和缓解相关急性髓系白血病的肿瘤微环境发生改变。Huang, Xin; Li, Minming; Wu, Ping; Deng, Chengxin; Lu, Zesheng; Wang, Yulian; Geng, Suxia; Luo, Chengwei Luo; Lai, Peilong; Du, Xin; Weng, Jianyu 分享 收藏 Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study每周 Selinexor、Bortizomib 和 Dexamethasone (SVd) 与每周两次 Bortizomib 和 Dexamethasone (Vd) 在中国复发性和难治性多发性骨髓瘤 (RRMM) 患者中的比较：Bench 研究的初步分析Lu, Jin; Geng, Liangquan; Chen, Lijuan; Liu, Peng; Zhong, Yuping; Liu, Zhuogang; Xia, Zhongjun; Mi, Jianqing; Li, Chunrui; Zhang, Xi; He, Yanjuan; Wei, Yongqiang; Fang, Baijun; Li, Fei; Cai, Zhen; Wang, Yafei; Huang, Dongping; Liu, Hong; Hou, Ming; Fu, Rong; Du, Xin; Fang, Xiaosheng; Zeng, Qingshu; Gao, Wen; Wang, Wei; Chang, Chunkang; Ouyang, Guifang; Liu, Jing; Weng, Jianyu; Huang, Xiaobing; Yu, Yang; Guo, Zhi; Zhao, Jun; Hou, Jian 分享 收藏 Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China奥维雷巴替尼疗法在加速期慢性髓系白血病患者中的应用：一项来自中国的多中心回顾性研究Yuan, Mengyao; Zhou, Li; Du, Xin; Weng, Jianyu; Yang, Linhua; Ma, Yanping; Zhao, Shasha; Liu, Zhenfang; Wen, Qin; Bai, Qingxian; Feng, Xianqi; Han, Yanqiu; Li, Aifang; Liu, Chunshui; Leng, Qing; Meng, Li; Wang, Baohong; Ran, Xuehong; Wang, Xiaodong; Zhang, Haiguo; Zeng, Yun; Zhang, Yanli; Jiang, Qian 分享 收藏 Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINEzanubrutinib与ibrutinib在中国复发/难治性慢性淋巴细胞白血病 (R/R CLL) 患者中的疗效和安全性得到改善: 高山亚组Zhou, Keshu; Wang, Tingyu; Pan, Ling; Xu, Wei; Jin, Jie; Zhang, Wei; Hu, Yu; Hu, Jianda; Feng, Ru; Li, Ping; Liu, Zhougang; Liu, Peng; Jing, Hongmei; Gao, Sujun; Zhang, Huilai; Yu, Kang; Wang, Zhao; Zhu, Xiongpeng; Sun, Zimin; Li, Fei; Yan, Dongmei; Weng, Jianyu; Fu, Lina; Wang, Liping; Salmi, Tommi; Wu, Kenneth; Qiu, Lugui 分享 收藏 Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experienceLi, Chao; Deng, Chengxin; Wu, Ping; Liu, Kaifan; Huang, Xin; Li, Mingmin; Chen, Xiaomei; Geng, Suxia; Lai, Peilong; Weng, Jianyu; Du, Xin 分享 收藏 分享 收藏 Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialAponermin或安慰剂联合沙利度胺和地塞米松治疗复发或难治性多发性骨髓瘤 (CPT-MM301): 一项随机，双盲，安慰剂对照的3期试验Xia, Zhongjun; Leng, Yun; Fang, Baijun; Liang, Yang; Li, Wei; Fu, Chengcheng; Yang, Linhua; Ke, Xiaoyan; Jiang, Hua; Weng, Jianyu; Liu, Li; Zhao, Yaozhong; Zhang, Xuejun; Huang, Zhongxia; Liu, Aichun; Shi, Qingzhi; Gao, Yuhuan; Chen, Xiequn; Pan, Ling; Cai, Zhen; Wang, Zhao; Wang, Yafei; Fan, Yaqun; Hou, Ming; Ma, Yigai; Hu, Jianda; Liu, Jing; Zhou, Jianfeng; Zhang, Xiaohong; Meng, Haitao; Lu, Xuzhang; Li, Fei; Ren, Hanyun; Huang, Bintao; Shao, Zonghong; Zhou, Hebing; Hu, Yu; Yang, Shifang; Zheng, Xiangjun; Wei, Peng; Pang, Hongyan; Yu, Wei; Liu, Yuzhang; Gao, Sujun; Yan, Lingzhi; Ma, Yanping; Jing, Hongmei; Du, Juan; Ling, Wei; Zhang, Jingyi; Sui, Weiwei; Wang, Fuxu; Li, Xin; Chen, Wenming 分享 收藏 Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm studyLiu, Hui; Xia, Linghui; Weng, Jianyu; Zhang, Fengkui; He, Chuan; Gao, Sujun; Jia, Jinsong; Chang, Alice C.; Lundberg, Pontus; Shi, Jane; Sima, Camelia S.; Sostelly, Alexandre; Sreckovic, Sasha; Xiao, Zhenyu; Zhang, Zilu; Fu, Rong 分享 收藏 Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phaseYang, Sen; Zhang, Xiaoshuai; Gale, Robert Peter; Du, Xin; Chen, Chun-yan; Weng, Jian-yu; Huang, Jian; Li, Fei; Zeng, Yun; Xiao, Zhen; Hu, Jian-da; Yang, Li-jie; Liu, Zhuo-gang; Li, Guo-hui; Sun, Xiu-li; Yang, Wei; Feng, Ru; Han, Yan-qiu; Jing, Yu; Xu, Na; Liu, Xiao-li; Liu, Zhen-fang; Wang, Xiao-dong; Wu, Shi-xin; Liang, Rong; Zhang, Yan-li; Yang, Yun-fan; Zhu, Huan-ling; Pan, Ling; Meng, Li; Zhao, Yan-hong; Yi, Hai; Liu, Yi-lan; Zhang, Wei-hua; Zheng, Yuan-jun; Zhou, Ze-ping; Chen, Su-ning; Qiu, Hui-ying; Li, Wei-ming; Jia, Zhi-lin; Bai, Yan-liang; Lin, Li-e; Liu, Bing-cheng; Liu, Chun-shui; Luo, Jian-min; Meng, Jun-xia; Sun, Zhi-qiang; Zhang, Yan-qing; Huang, Xiao-jun; Jiang, Qian 分享 收藏 Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathwayXu, Ruohao; Wu, Miao; Wang, Yawen; Li, Chao; Zeng, Lingji; Wang, Yulian; Xiao, Maozhi; Chen, Xiaomei; Geng, Suxia; Lai, Peilong; Du, Xin; Weng, Jianyu 分享 收藏 Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in miceChen, Xiaomei; Wang, Yulian; Huang, Xin; Geng, Suxia; Li, Chao; Zeng, Lingji; Huang, Lisi; Du, Xin; Weng, Jianyu; Lai, Peilong 分享 收藏 Validation of the imatinib-therapy failure modelZhang, Xiaoshuai; Gale, Robert Peter; Liu, Bingcheng; Huang, Jian; Zhang, Yanli; Du, Xin; Weng, Jianyu; Li, Weiming; Xu, Na; Liu, Xiaoli; Chen, Chunyan; Lin, Hai; Li, Guohui; Liang, Rong; Liu, Zhuogang; Wang, Xiaodong; Zhang, Yanqing; Han, Yanqiu; Liu, Chunshui; Hu, Jianda; Lin, Lie; Yang, Wei; Liu, Zhenfang; Meng, Li; Tu, Chuanqing; Zheng, Caifeng; Zhou, Zeping; Bai, Yanliang; Qiu, Huiying; Chen, Suning; Li, Fei; Guo, Jianxin; Liu, Zelin; Sun, Hui; Zhou, Li; Feng, Ru; Sun, Xiuli; Huang, Xiaojun; Jiang, Qian 分享 收藏 Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatmentYao, Danlin; Lai, Jing; Lu, Yuhong; Zhong, Jun; Zha, Xianfeng; Huang, Xin; Liu, Lian; Zeng, Xiangbo; Chen, Shaohua; Weng, Jianyu; Du, Xin; Li, Yangqiu; Xu, Ling 分享 收藏 Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemiaZhang, Lenghe; Zhou, Lijuan; Wang, Yulian; Li, Chao; Liao, Pengjun; Zhong, Liye; Geng, Suxia; Lai, Peilong; Du, Xin; Weng, Jianyu 分享 收藏 Mutant C/EBPα p30 alleviates immunosuppression of CD8+ T cells by inhibiting autophagy-associated secretion of IL-1β in AMLWang, Jun-Dan; Xu, Jue-Qiong; Zhang, Xue-Ning; Huang, Ze-Wei; Liu, Ling-Ling; Zhang, Ling; Lei, Xin-Xing; Xue, Man-Jie; Weng, Jian-Yu; Long, Zi-Jie 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
TRIALS.png)
OAAI